Page 359 - Read Online

Nedogoda et al. Vessel Plus 2018;2:37 Vessel Plus
DOI: 10.20517/2574-1209.2018.36

Original Article Open Access

Blood pressure control and vascular protection with
a fixed-dose combination of lisinopril + amlodipine +
rosuvastatin in hypertensive patients

Sergey V. Nedogoda, Elena V. Chumachek, Alla A. Ledyaeva, Vera V. Tsoma, Alla S. Salasyuk, Victoria O.
Smirnova, Victoria Yu. Hripaeva, Roman V. Palashkin, Ekaterina A. Popova

Department of Therapy and Endocrinology, Volgograd State Medical University, Ministry of Healthcare of the Russian Federation,
Volgograd 400066, Russian Federation.

Correspondence to: Dr. Sergey V. Nedogoda, Department of Therapy and Endocrinology, Tsiolkovskogo str, 1, Volgograd 400001,
Russian Federation. E-mail: nedogodasv@rambler.ru

How to cite this article: Nedogoda SV, Chumachek EV, Ledyaeva AA, Tsoma VV, Salasyuk AS, Smirnova VO, Hripaeva VY,
Palashkin RV, Popova EA. Blood pressure control and vascular protection with a fixed-dose combination of lisinopril + amlodipine +
rosuvastatin in hypertensive patients. Vessel Plus 2018;2:37. http://dx.doi.org/10.20517/2574-1209.2018.36

Received: 23 May 2018 First Decision: 27 Aug 2018 Revised: 26 Sep 2018 Accepted: 1 Oct 2018 Published: 6 Nov 2018
Science Editor: Alexander D. Verin Copy Editor: Cui Yu Production Editor: Zhong-Yu Guo

Abstract
Aim: Assessment of the possibility of the fixed-dose combination of lisinopril + amlodipine + rosuvastatin (Equamer) to
achieve further angioprotection in patients with arterial hypertension and high pulse wave velocity (PWV) despite the
previous combination antihypertensive therapy (AHT).

Methods: The 24-week open-label multi-center observational study involved 60 patients who received dual
combination AHT for 6 months. All patients underwent 24 h blood pressure (BP) monitoring, applanation tonometry
(determination of the augmentation index and central BP), measurement of the pulse wave velocity and laboratory
tests [blood lipids, fasting glucose test, homeostasis model assessment of insulin resistance (HOMA-IR), leptin,
ultra-sensitive C-reactive protein (us-CRP)] before and after switching to the fixed-dose combination of lisinopril +
amlodipine + rosuvastatin (Equamer).

Results: According to the office BP measurements, switching the patients from the dual combinations to the fixed-dose
combination of lisinopril + amlodipine + rosuvastatin has resulted in a further decrease of 14.3% in systolic BP (SBP) and
18.5% in diastolic BP (DBP). According to the 24 h BP monitoring data, the SBP has decreased by 16.1% and the DBP by 21.8%.
The combination of lisinopril + amlodipine + rosuvastatin has reduced the SBP by 14.4%, the augmentation index by 14.5%
and the central SBP by 8.1% (P < 0.01 vs. baseline). The fixed-dose combination of lisinopril + amlodipine + rosuvastatin has
provided a 44%-decrease in low-density lipoproteins, a 36.1%-decrease in triglycerids and a 10.3%-increase in high-
density lipoproteins (P < 0.01 vs. baseline). The use of the fixed-dose combination of lisinopril + amlodipine + rosuvastatin
has provided a definite decrease in the insulin resistance, as well as levels of us-CRP and leptin.

© The Author(s) 2018. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.vpjournal.net